Any time a deviation is made from the process in the batch production record, it has to be recorded, investigated and disposition. This presentation provides details on how this is done.
Operating Excellence is built on Corrective & Preventive ActionsAtanu Dhar
You see an issue and you simply set it right, but do you make the effort to find out what is the "corrective" action behind it, so that it never re-occurs?
And, do you take another extra step to come up with a "preventive" action - so that there is no other manner that issue comes up?
Overview on “Computer System Validation” CSVAnil Sharma
HI this is Anil Sharma, Executive Compliance in USV LTD. I want to share my brief knowledge on CSV with you. I hope my presentation will help you to understand basics of CSV.
https://quality.eqms.co.uk/blog/good-practice-in-the-pharmaceutical-industry
What is GxP? What is GxP important for the life science industry? How can you use software to comply with GxP
Good Practice in the Life Science industry
Operating Excellence is built on Corrective & Preventive ActionsAtanu Dhar
You see an issue and you simply set it right, but do you make the effort to find out what is the "corrective" action behind it, so that it never re-occurs?
And, do you take another extra step to come up with a "preventive" action - so that there is no other manner that issue comes up?
Overview on “Computer System Validation” CSVAnil Sharma
HI this is Anil Sharma, Executive Compliance in USV LTD. I want to share my brief knowledge on CSV with you. I hope my presentation will help you to understand basics of CSV.
https://quality.eqms.co.uk/blog/good-practice-in-the-pharmaceutical-industry
What is GxP? What is GxP important for the life science industry? How can you use software to comply with GxP
Good Practice in the Life Science industry
FDA WARNING LETTER IS A OFFICIAL LETTER FROM USFDA TO A MANUFACTURING FIRM TO NOTICE THE SERIOUS VIOLATION FOUND AT THE FDA INSPECTION AT FIRM AND THE CORRECTIVE ACTION SHOULD TO TAKEN BY FIRM TO OVERCOME THE VIOLATION FOR FDA APPROVAL
This presentation describes approaches for software validation used to automate laboratory research procedures, consolidate data collection and analysis and/or run sophisticated QC or manufacturing operations.
Several approaches to software validation exist and may be appropriate for a specific project.
The scope of any validation effort depends upon a number of factors
Size and complexity of the software,
Origin of the software (custom vs. off-the-shelf) and
Whether the functions are critical or non-critical in nature.
By effectively planning the process, validation time and resources can be reduced while meeting regulatory requirements.
Explanation of ISO standard 13485 (QUALITY MANAGEMENT SYSTEM OF MEDICAL DEVICES) in a clarified way to understand it well in a simplified way through this mode. Your comments are appreciated.
An introduction to Life Sciences Computer System Validation, applicable regulation, SDLC phases, software categorisation, risk/ change/ deviation management, validation deliverable, risk based approach, regulatory inspection, audit findings, causes of compliance failure, key concepts in CSV etc.
21 CFR-FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES...ICHAPPS
TRAINING PROGRAMME ON
21CFR PARTS-210 AND 211
QUALITY ASSURANCE
Slideshow About 21 CFR
“Every product must be fit for its intended purpose”
“Every product must be fit for its intended purpose”
FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES- UNITED STATES OF AMERICA
FDA WARNING LETTER IS A OFFICIAL LETTER FROM USFDA TO A MANUFACTURING FIRM TO NOTICE THE SERIOUS VIOLATION FOUND AT THE FDA INSPECTION AT FIRM AND THE CORRECTIVE ACTION SHOULD TO TAKEN BY FIRM TO OVERCOME THE VIOLATION FOR FDA APPROVAL
This presentation describes approaches for software validation used to automate laboratory research procedures, consolidate data collection and analysis and/or run sophisticated QC or manufacturing operations.
Several approaches to software validation exist and may be appropriate for a specific project.
The scope of any validation effort depends upon a number of factors
Size and complexity of the software,
Origin of the software (custom vs. off-the-shelf) and
Whether the functions are critical or non-critical in nature.
By effectively planning the process, validation time and resources can be reduced while meeting regulatory requirements.
Explanation of ISO standard 13485 (QUALITY MANAGEMENT SYSTEM OF MEDICAL DEVICES) in a clarified way to understand it well in a simplified way through this mode. Your comments are appreciated.
An introduction to Life Sciences Computer System Validation, applicable regulation, SDLC phases, software categorisation, risk/ change/ deviation management, validation deliverable, risk based approach, regulatory inspection, audit findings, causes of compliance failure, key concepts in CSV etc.
21 CFR-FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES...ICHAPPS
TRAINING PROGRAMME ON
21CFR PARTS-210 AND 211
QUALITY ASSURANCE
Slideshow About 21 CFR
“Every product must be fit for its intended purpose”
“Every product must be fit for its intended purpose”
FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES- UNITED STATES OF AMERICA
INHIBITION EFFECT OF SCHIFF BASE COMPOUNDS ON THE CORROSION OF IRON IN NITRIC ACID AND SODIUM HYDROXIDE SOLUTIONS
Loutfy H. Madkour* and U.A. Zinhome**
SBL offers a comprehensive range of geospatial services that address the varied needs of consumers, businesses, and government agencies.We have highly qualified team members to provide you with good services in terms of perfection, time, and cost.
InstantGMP Compliance Series - Improving Batch Production RecordsInstantGMP™
Batch record violations were frequently cited during FDA inspections of dietary supplement manufacturers. This presentation provides some guidance on what is needed for batch records to be in compliance with GMPs.
InstantGMP Compliance Series - Improving Quality through In-Process ControlInstantGMP™
In-Process controls are needed at each step of a manufacturing procedure where the control of a critical process can affect the quality of the final product. This presentation explains how to set and use in-process controls.
Instant GMP Compliance Series -Better Compliance through Master Manufacturing...InstantGMP™
FDA inspections are increasing every year and they have published the results on their website. 50% of dietary supplement manufacturers are not in GMP compliance and 1 in 4 dietary supplement companies have received a warning letter which could result in a significant enforcement action such as halting production and distribution. Many of these producers received citation because they were not using Master Manufacturing Records.
Computerized System Validation Business Intelligence SolutionsDigital-360
Executive Summary
Regulated pharmaceutical, biotech and medical device companies are challenged to develop manufacturing capabilities quickly and cost-effectively while at the same time safeguarding product quality and patient safety.
Validation has been an essential part of regulated industries for over 20 years, yet as the field has evolved, little has changed in the business, or manual, approach to validation.
Instant GMP Compliance Series - Improving DocumentationInstantGMP™
The FDA enforces the Dietary Supplement Health and Education Act (DSHEA) law by inspecting dietary supplement manufacturers, packagers, labelers and holders for Current Good Manufacturing Practices (cGMPs) compliance. One of the main issues they found was the lack of proper documentation. This presentation provides an overview of the documentation that is needed for cGMP compliance.
Modern business drivers are continually pushing to reduce the time it takes to get a product or service to market, reduce the risk and cost associated with that, and to improve quality.
In laboratories, delivering an analytical result that’s ‘right first time’ (RFT) is the answer. There is no reprocessing data or re-running injections and no out of specification (OOS) results or reporting/calculation errors.
Using chromatography data system tools for RFT analysis automatically gives high quality of results and confidence in results, lower cost of analysis, improved lab efficiency, and faster release to market and return on investment (ROI).
Controlling consists of verifying whether everything occurs in conformities with the plans adopted, instructions issued and principles established. Controlling ensures that there is effective and efficient utilization of organizational resources so as to achieve the planned goals. Controlling measures the deviation of actual performance from the standard performance, discovers the causes of such deviations and helps in taking corrective actions.
Not having the ability to identify and rapidly respond to an abnormality means risking potential line shutdown, re-work, or maybe even a recall. Learn the steps needed to formalize and implement a proactive abnormality management program - including methods to error-proof your operations.
Moving From Paper-Based Systems to Electronic Batch Records - InstantGMP™InstantGMP™
Technology is constantly evolving around us, and yet many manufacturers continue using paper-based systems to manage and record their activities while manufacturing. In recent times, many of these manufacturers, especially in pharmaceuticals and biotech, are making the move to a Manufacturing Execution System (MES) and Electronic Batch Records (EBR).
InstantGMP MD is the latest version of InstantGMP's good manufacturing practices software. MD brings manufacturers of medical devices into cGMP compliance by coming fully validated and compliant with Part 820.
Formulation Development of Poorly Soluble DrugsInstantGMP™
Poorly soluble drugs are the nemesis of formulation development scientists. Bruce Rehlaender the big issues and points out some approaches for dealing with these drugs and improving their bioavailability.
InstantGMP Compliance Series - Facility DesignInstantGMP™
The design of facilities used in the manufacturing of dietary supplements must meet strict requirements for preventing mix-ups and cross contamination. This presentation describes how this can be done.
InstantGMP Compliance Series - EquipmentInstantGMP™
Equipment used in producing dietary supplements fall under Good Manufacturing Practices. This presentation offers guidance on how to keep equipment in compliance.
InstantGMP Compliance Series - Improving SpecificationsInstantGMP™
The FDA requires specifications for identity, strength, purity and composition for dietary supplement products. This presentation explains how to meet these GMP requirements.
Instant GMP Compliance Series for Dietary Supplements – Cost of ComplianceInstantGMP™
This presentation is one in a series of presentations that focus on good manufacturing practices and cGMP compliance for dietary supplements manufacturing. It’s brought to you by the quality and manufacturing experts at InstantGMP in the hope that it will help you avoid any cGMP compliance issues in your shop.
Instant GMP Compliance Series for Dietary Supplements – IntroductionInstantGMP™
Since 2010, the FDA has stepped up their inspections of dietary supplement manufacturers. At least 1 in 4 of those companies inspected received a Warning Letter to improve cGMP compliance or suffer regulatory action. This prompted us to prepare a series of presentations that will focus on good manufacturing practices and cGMP compliance for dietary supplements manufacturing. It’s brought to you by the quality and manufacturing experts at InstantGMP in the hope that it will help you avoid any cGMP compliance issues in your shop.
Any company involved in the dietary supplement business has to establish and to follow GMPs to ensure that packaging and labeling is done as specified in the master manufacturing record and to ensure the quality of the product that reaches the market. The presentation provides an overview of these requirements.
GMP Manufacturing for Worldwide Clinical Trials InstantGMP™
This presentation describes the complex process of manufacturing clinical trial materials using examples from the InstantGMP manufacturing execution system. InstantGMP is an electronic batch record system for small pharmaceutical operations and is ideal for manufacturing CTM or tracking inventory worldwide.
Pharmaceutical manufacturing has become a significant industry in India. It has been estimated that has the third largest pharmaceutical industry by volume We will examine how well they comply with Good Manufacturing Practices (GMP).
Specifications for GMP Dietary SupplementsInstantGMP™
Every manufacturer or distributor of dietary supplements has to be in compliance with Good Manufacturing Practices (GMP) requirements. GMP compliance for dietary supplements requires that products must meet specifications for identity, purity, strength, and composition and limits on contaminants. Also specifications are necessary to prevent adulteration as a result of what the manufacturer may do or fail to do in its manufacturing operation.
2. Deviations
• Triggered by any unanticipated occurrence could
result in adulteration
• Must be noted in batch record
• Quality must conduct a material review
• Then make a disposition decision
• May not reprocess a batch that deviates unless
approved by Quality
Electronic cGMP Manufacturing Execution System
3. Problems with Deviations
• Warning letters issued to firms who failed to
record and resolve production deviations
• One firm used ingredients other than the ones
specified
• Another firm did not conduct an investigation of
retested samples that failed specifications
• A firm claimed to have established deviation
procedures, but provide no documentation
Electronic cGMP Manufacturing Execution System
4. Why Managing Deviations Is Important
• Intention is to make uniform, high quality products
• Deviations may indicate product is not under control
• May indicate that master formula may need updating
based on variations in raw materials or dietary ingredients
• Quality needs to review and disposition each deviation
• Lets an independent quality group make sure product that
reaches the market is free from defects
Electronic cGMP Manufacturing Execution System
5. Definitions
• OOS – Out of Specification
• CAPA – Corrective and Preventive Action
• Corrective Action – eliminate cause of an
existing undesirable situation in order to prevent
a recurrence
• Preventive Action – eliminate the cause of a
potential undesirable situation in order to prevent
an occurrence
Electronic cGMP Manufacturing Execution System
6. Out of Specification
• OOS - any value that does not meet the acceptance
criteria of a specification
• Triggers an investigation plan
• Initial phase - the laboratory results are challenged by
retesting and comparing to a retain sample to
• Second phase - investigation of the manufacturing
processes
• Quality must make a disposition decision and decide
whether the batch is OK or should be rejected
Electronic cGMP Manufacturing Execution System
7. Investigations
• Investigations may be initiated due to:
– Confirmed Out-Of-Specification (OOS) results
– Out-of-Trend (OOT) - atypical results that deviate
from expected or historical data, but still meets
specifications
– Failure of a component, excipient or in-process test
– Unplanned disruption in production
– Unplanned deviations from approved procedures,
methods or specifications
Electronic cGMP Manufacturing Execution System
8. Corrective and Preventative Actions
• CAPA log needed for recording deviations
• Identify the specific deviation or unanticipated
occurrence
• Describe the investigation
• Evaluate whether or not the deviation resulted
from or could lead to a failure
• Identify actions to correct and prevent a
recurrence
Electronic cGMP Manufacturing Execution System
9. Determine the Scope
• Scope includes:
– time frames during which the problem occurred
– number of times the problem occurred
– the number and identity of products or materials
involved
– locations (including vendors) involved.
• Determine the relevant events leading up to and
surrounding the event. Determine what happened, how
it happened, and who, when and where.
• Clearly define the problem
Electronic cGMP Manufacturing Execution System
10. Determine Root Causes
• Determine possible and probable causes of the problem
• Determines why the problem occurred
• Root causes will typically fall into one of three categories:
– System design: Are procedures sufficient? Are other
process components sufficient (materials, equipment,
facilities, personnel).
– System implementation: What does, or can management do
to ensure that procedures are followed?
– Performance: Is this an individual performance issue?
Electronic cGMP Manufacturing Execution System
11. Determine Corrective/Preventive Actions
• Use various tools and techniques, such as
brainstorming, cause and effect analysis and
statistical tools
• Involve people closest to the problem
• Select the most effective or cost effective
corrective/preventive action
• Document justifications
Electronic cGMP Manufacturing Execution System
12. Develop CAPA Plans
• Redesign systems and processes
• Implement remedial training is needed,
• Assure that there is no further performance of
the task until the necessary re-training is
complete
• Set target dates and assign individuals
responsible for implementation
• Use measurable outcomes to evaluate the
effectiveness of the preventive actions
Electronic cGMP Manufacturing Execution System
14. Benefits of Electronic Manufacturing
• More efficient than manual systems
• Shrink or eliminate redundant processes and
forms
• Trim time and overhead costs
• Reduce errors, omissions and deviations
• Provide opportunities to reorganize and update
processes
• Increases throughput, quality and margins
Electronic cGMP Manufacturing Execution System
15. InstantGMP™
Find more videos on GMP
Manufacturing in the Resource
Center at
www.instantgmp.com
Editor's Notes
The staff at InstantGMP prepared this Compliance Series for GMPs in Dietary Supplements to focus on good manufacturing practices and GMP compliance. These are brought to you by our quality and manufacturing experts in the hope that it will help you avoid any GMP compliance issues in your shop. This presentation will address improving compliance through managing deviations.
GMP regulations require you to review the results of any deviation or unanticipated occurrence that could result in adulteration. The deviation should be noted in the batch production record along with documentation that describes your investigation into the cause of the deviation or the unanticipated occurrence. Quality must conduct a material review and make a disposition decision if there is such an unanticipated occurrence during manufacturing. If you want to reprocess a batch with a deviation, Quality must review and give approval.
A dietary supplement manufacturer in NY was issued a warning letter for violations of GMP regulations. The FDA noted in their investigations that several of the company’s batch production records showed deviations from the Master Manufacturing Record. For example, the company used ingredients other than the ones specified, but there was no documentation that they conducted a material review or made a disposition decision. Another firm received a warning letter because their quality group did not conduct a material review and make a disposition decision for a manufacturing deviation where retesting was done. The quality group was not required by the firm’s procedures to investigate retested samples which failed their specification and the quality group did not make a disposition decision for this deviation. A firm claimed to have established deviation procedures, but provide no documentation. After an FDA inspection, a firm stated that they had implemented a deviation program and training was given. When the investigator returned, there was no documentation showing that the firm had complied with their own procedures.
Detecting and managing deviations is important for many reasons. The intent is to make sure every batch of product made from the same master formula is uniform and meets the quality specifications. Since final product testing is not required for all dietary supplement products, meeting in-process controls and doing the manufacturing according to the written procedure is necessary to assure good quality of the final product. When deviations or unanticipated occurrences come up during manufacturing, they may be an indication that the product is not under control and therefore may not be able to be sold. The FDA requires quality personnel to conduct a material review and make a disposition decision if a batch deviates from the Master Manufacturing Record, including not completing steps or deviating from specifications. Deviations may also indicate that master manufacturing formulations may need to be updated based on variations in in-coming raw materials or dietary ingredients. When the QC unit is independent of manufacturing operations, it can provide an objective opinion about quality that assures the firm produces and distributes product that are free from defects. In situations where there is no quality unit to review deviations or deviation are not reviewed, economic pressures can prevail and decisions to release product to market may not be based on sound quality principles. The key is determining whether the deviations impacts the product quality and if so, determining if the batch should be rejected.
Some definitions of common terms and abbreviations will help in managing deviations. OOS is an Out of Specification result. CAPA is a Corrective and Preventive Action log or register. A Corrective Action is taken to eliminate the cause of an existing non-conformity, defect or other undesirable situation in order to prevent recurrence. A Preventive Action is taken to eliminate the cause of a potential non-conformity, defect or other undesirable situation in order to prevent occurrence.
An out of specification result is any value that does not meet the acceptance criteria of a specification. An OOS typically triggers an investigation plan. In the initial phase, the laboratory results are challenged by retesting the original sample and a retain sample to compare results. If the original sample is still OOS, then an investigation of the manufacturing processes is started. Batch records, production processes, equipment status and operation actions are all evaluated. At the end of the evaluation, Quality must make a disposition decision and decide whether the batch is OK or should be rejected.
Investigations may be initiated due to a variety of circumstances, including, but not limited to: a confirmed Out-Of-Specification (OOS) results from a laboratory investigation or an Out-of-Trend (OOT) or atypical data/results that deviate from expected or historical data, but still meets specification requirements. An investigation could be triggered by the failure of a starting material or excipient, or an in-process test. If there are unplanned disruption in production (i.e., mechanical or control system failure, utility disruption) or unplanned deviations from approved procedures, methods or specifications, an investigation may be initiated. Any other unprecedented event that has potential impact to product safety, identity, quality, efficacy, purity, strength, regulatory filing and/or stability could be a cause for an investigation.
Corrective and preventive action plans are needed to address the root cause of a deviation and to prevent a recurrence. CAPA plans have to be monitored to verify completion and effectiveness. A Corrective and Preventative Actions (CAPA) log is needed to record deviations. It should identify the specific deviation or the unanticipated occurrence, describe the investigation, evaluate whether or not the deviation resulted from or could lead to a failure, identify the actions taken to correct and prevent a recurrence, explain what was done with the component, dietary supplement, packaging, or label and explain a scientifically valid reason for any reprocessing work. The CAPA log allows trends to be identified and a record of resolution of programs to be kept.
The Scope of a CAPA plan should be determined. The scope includes the time frames during which the problem occurred, the number of times the problem occurred, the number and identity of products or materials involved, and the locations (vendors) involved. It should determine the relevant events leading up to and surrounding the event, determine what happened, how it happened, and who, when and where. Overall, it should clearly define the problem.
Determine possible and probable root causes of the problem. The root cause analysis determines why the problem occurred. Once root causes are determined, they will typically fall into one of three categories: System design: Are procedures sufficient? Are other process components sufficient (materials, equipment, facilities, personnel). System implementation: What does, or can management do to ensure that procedures are followed? Performance: Is this an individual performance issue?
Determine Possible and Probable Corrective/Preventive Actions. Wherever possible or necessary, use various tools and techniques, such as brainstorming, cause and effect analysis and statistical tools etc. Involve people closest to the problem. Select the most effective or cost effective corrective/preventive actions as appropriate and then document your justification.
When developing CAPA plans, you may need to redesign systems and processes. You should implement remedial training when needed and then aAssure that there is no further performance of the task until the necessary re-training is completed. You should set target dates and assign the individuals responsible for implementation. It’s important to use measurable outcomes so you can evaluate the effectiveness of the preventive actions.
InstantGMP automatically manages deviations in their electronic batch records. Any time a deviation comment is written ina batch record step, that step is flagged so that Quality is alerted to the event. Quality must review and conduct their investigation, then sign off on each deviation their digital signature before the batch can be completed and dispositioned.
There are many reasons that companies will want to adopt an electronic manufacturing system. They are more efficient than manual systems. For example, they can shrink or eliminate the redundant process and forms that occur in manual systems. They can trim time and costs compared to manually compiling and reviewing documentation. They can reduce errors, omissions and deviations. Probably the most important advantage is that a transition to an electronic system can provide opportunities to reorganize and to update processes to make the whole plant work better. All of these benefits taken together will result in increased throughput, quality and margins.
Thank you for viewing our series on GMPs. You can find more videos and articles on GMP manufacturing in our Resource Center at www.InstantGMP.com.